Australia, Dec. 3 -- Ring Therapeutics Inc., owns the trademark (2587920) for 'RINGTX' till July 29, 2035.
Status: protected:
Registered/protected
Classes: 5 [Encapsulated nucleic acids for use as biological therapeutics in gene therapy for the treatment of human diseases and disorders; pharmaceutical preparations for use in gene therapy for the treatment of rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune diseases, autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases.] and 40 [Custom manufacture of anelloviruses.]
Type of Mark: Fancy
Date of Acceptance: Sept. 25
Registration Advertised: Dec. 2
For further details contact Greenfield & Sacks P.C. Christina M. Licursi Wolf.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2587920.
Disclaimer: Curated by HT Syndication.
